Literature DB >> 18810328

PK/PD modelling and beyond: impact on drug development.

Douwe D Breimer1.   

Abstract

PK/PD modelling will play an increasingly important role in drug development, because it will identify key properties of a drug in vivo, allowing the characterization and prediction of the time course of drug effects under physiological and pathological conditions (intensity and duration). It has developed from a descriptive to a mechanism-based approach, taking the relevant processes on the causal path between drug administration and drug effect into account. Recent developments and insights from systems biology and systems pharmacology will provide new information on the complexities of disease associated with the identification of multiple targets for drug treatment. This will give rise to new opportunities of drug combinations, which can only be developed rationally through the appropriate application of dynamical systems-based PK/PD models.

Entities:  

Mesh:

Year:  2008        PMID: 18810328     DOI: 10.1007/s11095-008-9717-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Future challenges for drug delivery research.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1998-09-07       Impact factor: 15.470

Review 2.  Systems biology: a brief overview.

Authors:  Hiroaki Kitano
Journal:  Science       Date:  2002-03-01       Impact factor: 47.728

Review 3.  Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo.

Authors:  Daniël M Jonker; Sandra A G Visser; Piet H van der Graaf; Rob A Voskuyl; Meindert Danhof
Journal:  Pharmacol Ther       Date:  2004-12-23       Impact factor: 12.310

Review 4.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

Authors:  Meindert Danhof; Joost de Jongh; Elizabeth C M De Lange; Oscar Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 5.  Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies.

Authors:  Adam Cohen
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 6.  Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Authors:  D D Breimer; M Danhof
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

Review 7.  Drug treatment effects on disease progression.

Authors:  P L Chan; N H Holford
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

  8 in total
  8 in total

Review 1.  Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview.

Authors:  Zinnia P Parra-Guillén; Gloria González-Aseguinolaza; Pedro Berraondo; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2010-04-13       Impact factor: 4.200

Review 2.  The role of population PK-PD modelling in paediatric clinical research.

Authors:  Roosmarijn F W De Cock; Chiara Piana; Elke H J Krekels; Meindert Danhof; Karel Allegaert; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2010-03-26       Impact factor: 2.953

Review 3.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

4.  Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research.

Authors:  Chiara Piana; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

Review 5.  Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

Authors:  Francesco Bellanti; Bertil Kågedal; Oscar Della Pasqua
Journal:  Eur J Clin Pharmacol       Date:  2011-02-02       Impact factor: 2.953

6.  A systems approach for tumor pharmacokinetics.

Authors:  Greg Michael Thurber; Ralph Weissleder
Journal:  PLoS One       Date:  2011-09-14       Impact factor: 3.240

7.  Drug design for ever, from hype to hope.

Authors:  G Seddon; V Lounnas; R McGuire; T van den Bergh; R P Bywater; L Oliveira; G Vriend
Journal:  J Comput Aided Mol Des       Date:  2012-01-18       Impact factor: 3.686

8.  Pharmacokinetics and Pharmacodynamics of (S)-Ketoprofen Co-Administered with Caffeine: A Preclinical Study in Arthritic Rats.

Authors:  Raúl Medina-López; Nancy Vara-Gama; Olivia Soria-Arteche; Luis A Moreno-Rocha; Francisco J López-Muñoz
Journal:  Pharmaceutics       Date:  2018-01-26       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.